pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·9h ago·1 min read
save

Oxford study offers model showing statins pose minimal muscle disorder risk, a tool against health misinformation

Aug 13, 2026·read at STAT ↗Positive

The piece highlights how fearmongering about statins has surged online, with claims that the drugs damage the brain, liver and muscles. The authors argue that clearer evidence at the point of claim can undermine this misinformation.

Researchers at Oxford analyzed health records of 5.7 million English patients to create a risk model for serious muscle disorders linked to statin use. The model found that 99.6% of people deemed eligible for statins were at low risk of such side effects.

Clinicians could use this model to calculate an individual’s risk and reassure worried patients, offering a data‑driven counterpoint to alarmist narratives.

If widely adopted, tools like this could weaken the business model of health misinformation by giving patients reliable, personalized evidence when they encounter dubious claims.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: How to disrupt the health misinformation business model”

read at STAT ↗
1,413 words · retrieved 7h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Mayo Clinic2HOOKIPA Pharma Inc.The Medicines Co
drugs
OMEGAVENObesitycinnamon
topics
Cardiology5Vaccines4Hyperlipidemia3Big Pharma2Hepatology2Psychiatry & CNS2EpilepsyObesityOncologyType 2 Diabetes

related stories

  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Dec 22Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series BFierce Biotech
  • Jul 1412 ideas for tackling the U.S. alcohol epidemicSTAT
  • Jun 11HHS responds coolly to paper on alcohol riskSTAT
  • Jun 3Is the military fueling eating disorders?STAT